Adenylosuccinate synthetase from Cryptococcus neoformans complexed with GDP and IMP

Experimental Data Snapshot

  • Resolution: 1.53 Å
  • R-Value Free: 0.186 
  • R-Value Work: 0.134 
  • R-Value Observed: 0.135 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Disruption of de Novo Adenosine Triphosphate (ATP) Biosynthesis Abolishes Virulence in Cryptococcus neoformans.

Blundell, R.D.Williams, S.J.Arras, S.D.Chitty, J.L.Blake, K.L.Ericsson, D.J.Tibrewal, N.Rohr, J.Koh, Y.Q.Kappler, U.Robertson, A.A.Butler, M.S.Cooper, M.A.Kobe, B.Fraser, J.A.

(2016) ACS Infect Dis 2: 651-663

  • DOI: https://doi.org/10.1021/acsinfecdis.6b00121
  • Primary Citation of Related Structures:  
    5I33, 5I34

  • PubMed Abstract: 

    Opportunistic fungal pathogens such as Cryptococcus neoformans are a growing cause of morbidity and mortality among immunocompromised populations worldwide. To address the current paucity of antifungal therapeutic agents, further research into fungal-specific drug targets is required. Adenylosuccinate synthetase (AdSS) is a crucial enzyme in the adeosine triphosphate (ATP) biosynthetic pathway, catalyzing the formation of adenylosuccinate from inosine monophosphate and aspartate. We have investigated the potential of this enzyme as an antifungal drug target, finding that loss of function results in adenine auxotrophy in C. neoformans, as well as complete loss of virulence in a murine model. Cryptococcal AdSS was expressed and purified in Escherichia coli and the enzyme's crystal structure determined, the first example of a structure of this enzyme from fungi. Together with enzyme kinetic studies, this structural information enabled comparison of the fungal enzyme with the human orthologue and revealed species-specific differences potentially exploitable via rational drug design. These results validate AdSS as a promising antifungal drug target and lay a foundation for future in silico and in vitro screens for novel antifungal compounds.

  • Organizational Affiliation

    Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland , Brisbane, Queensland 4072, Australia.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Adenylosuccinate synthetase
A, B
441Cryptococcus neoformans var. grubii H99Mutation(s): 0 
Gene Names: CNAG_02858
Find proteins for J9VI09 (Cryptococcus neoformans var. grubii serotype A (strain H99 / ATCC 208821 / CBS 10515 / FGSC 9487))
Explore J9VI09 
Go to UniProtKB:  J9VI09
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupJ9VI09
Sequence Annotations
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Resolution: 1.53 Å
  • R-Value Free: 0.186 
  • R-Value Work: 0.134 
  • R-Value Observed: 0.135 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 55.807α = 90
b = 100.774β = 90
c = 163.798γ = 90
Software Package:
Software NamePurpose
XDSdata reduction
Aimlessdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2016-08-24
    Type: Initial release
  • Version 1.1: 2016-11-16
    Changes: Database references
  • Version 1.2: 2023-09-27
    Changes: Data collection, Database references, Derived calculations, Refinement description